Department of Cell Signaling, Institute of Molecular Biology and Genetics, NAS of Ukraine, 150, Zabolotnogo str., Kyiv, Ukraine.
Diagn Pathol. 2012 Nov 26;7:161. doi: 10.1186/1746-1596-7-161.
On the past decade a plethora of investigations were directed on identification of molecules involved in breast tumorogenesis, which could represent a powerful tool for monitoring, diagnostics and treatment of this disease. In current study we analyzed six previously identified medullary breast carcinoma autoantigens including LGALS3BP, RAD50, FAM50A, RBPJ, PABPC4, LRRFIP1 with cancer restricted serological profile in different histological types of breast cancer.
Semi-quantitative immunohistochemical analysis of 20 tissue samples including medullary breast carcinoma, invasive ductal carcinoma, invasive lobular carcinoma and non-cancerous tissues obtained from patients with fibrocystic disease (each of five) was performed using specifically generated polyclonal antibodies. Differences in expression patterns were evaluated considering percent of positively stained cells, insensitivity of staining and subcellular localization in cells of all tissue samples.
All 6 antigens predominantly expressed in the most cells of all histological types of breast tumors and non-cancerous tissues with slight differences in intensity of staining and subcellular localization. The most significant differences in expression pattern were revealed for RAD50 and LGALS3BP in different histological types of breast cancer and for PABPC4 and FAM50A antigens in immune cells infiltrating breast tumors.
This pilot study made possible to select 4 antigens LGALS3BP, RAD50, PABPC4, and FAM50A as promising candidates for more comprehensive research as potential molecular markers for breast cancer diagnostics and therapy.
The virtual slides' for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1860649350796892.
在过去的十年中，大量的研究致力于鉴定参与乳腺癌发生的分子，这可能成为监测、诊断和治疗这种疾病的有力工具。在目前的研究中，我们分析了六个先前鉴定的乳腺髓样癌自身抗原，包括 LGALS3BP、RAD50、FAM50A、RBPJ、PABPC4 和 LRRFIP1，它们在不同组织学类型的乳腺癌中具有癌症特异性的血清学特征。
使用专门生成的多克隆抗体，对 20 个组织样本（包括乳腺髓样癌、浸润性导管癌、浸润性小叶癌和来自纤维囊性疾病患者的非癌组织，每个组织类型各 5 个）进行半定量免疫组织化学分析。考虑到所有组织样本中阳性染色细胞的百分比、染色的不敏感性和细胞内定位的差异，评估了表达模式的差异。
所有 6 种抗原主要在所有组织学类型的乳腺癌和非癌组织中的大多数细胞中表达，染色强度和细胞内定位略有不同。在不同组织学类型的乳腺癌中，RAD50 和 LGALS3BP 的表达模式差异最大，而在浸润性乳腺癌的免疫细胞中，PABPC4 和 FAM50A 抗原的表达模式差异最大。
这项初步研究使我们能够选择 4 种抗原（LGALS3BP、RAD50、PABPC4 和 FAM50A）作为更全面研究的候选物，作为乳腺癌诊断和治疗的潜在分子标志物。
本文的虚拟幻灯片可在此处找到：http://www.diagnosticpathology.diagnomx.eu/vs/1860649350796892.
